Compounds in development may offer advantages over semaglutide that change the treatment duration calculus
Tailoring Your Semaglutide Treatment Options Klinic offers numerous FDA-approved semaglutide and GLP-1 weight loss options to suit individual preferences and requirements
GLP-1 users are more active and feel better Americans who have been using GLP-1 medication for weight loss have found that theyre more active in life (42%), with exercise (41%), and sexually (29%)

Three million members of CVS Caremarks clients now enjoy access to clinical weight loss program with proven results, high satisfaction WOONSOCKET, R.I., March 14, 2025 CVS Health (NYSE: CVS) released compelling data today from the CVS Weight Management TM program in which participants achieved more than 15% weight loss on average, including existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians on diet and lifestyle.* Before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support.* The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients' plan members trying a lifestyle-first approach and additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management medications like GLP-1s

Shifting estrogen levels affect where fat is stored
From week 8 onward, the mice were divided into two groups: one group continued on the established HCD